Skip to main content
Erschienen in: American Journal of Clinical Dermatology 4/2006

01.08.2006 | Review Article

Nephrogenic Fibrosing Dermopathy

A Comprehensive Review for the Dermatologist

verfasst von: Dr Noah Scheinfeld

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Nephrogenic fibrosing dermopathy (NFD) is an acquired, idiopathic, chronic, progressive eruption of the skin sometimes accompanied by systemic fibrosis that occurs in the context of renal failure. The age of patients with NFD ranges from 8 to 87 years at the time of onset, with a mean age of 46.4 years. Most cases have been reported in the US and Europe, but recently cases have also been reported in India. About 175 cases have been noted in a registry established for NFD patients. Even in the setting of renal disease, NFD still occurs rarely and its cause is unknown. Patients present with hard, indurated, sometimes peau d’orange plaques. They often show a distinctive physical appearance, with elbows and knees angled inward, and most patients complain of a loss of range of motion. Histology demonstrates thickened collagen bundles with surrounding clefts, mucin, and a proliferation of fibroblasts and elastic fibers, sometimes with reticular, dermal, large epithelioid or stellate spindle cells. Fibrosis of NFD can affect the internal organs and thus the term nephrogenic systemic fibrosis has been used by some analysts to describe this fibrosing process. The fibrosis of NFD appears to be due to the effects of a cell referred to as the circulating fibrocyte. Rare cases of partial-to-complete spontaneous resolution have been reported in the absence of specific therapy. Treatments yield inconsistent results and include restoration of renal function, extracorporeal photopheresis, photodynamic therapy, high-dose intravenous immunoglobulin, and other immunosuppressive therapies.
Literatur
1.
Zurück zum Zitat Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000; 356: 1000–1PubMedCrossRef Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000; 356: 1000–1PubMedCrossRef
2.
Zurück zum Zitat Cowper SE. The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR). Nephrogenic fibrosing dermopathy [NFD/NSF website], 2001–2006. [online]. Available from URL: http://www.icnfdr.org/ [Accessed 2006 Jul 13] Cowper SE. The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR). Nephrogenic fibrosing dermopathy [NFD/NSF website], 2001–2006. [online]. Available from URL: http://​www.​icnfdr.​org/​ [Accessed 2006 Jul 13]
4.
Zurück zum Zitat Neudecker BA, Stern R, Mark LA, et al. Scleromyxedema-like lesions of patients in renal failure contain hyalmonan: a possible pathophysiological mechanism. J Cutan Pathol. 2005; 32: 612–5PubMedCrossRef Neudecker BA, Stern R, Mark LA, et al. Scleromyxedema-like lesions of patients in renal failure contain hyalmonan: a possible pathophysiological mechanism. J Cutan Pathol. 2005; 32: 612–5PubMedCrossRef
5.
Zurück zum Zitat Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermalot. 2003; 48: 55–60CrossRef Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermalot. 2003; 48: 55–60CrossRef
6.
Zurück zum Zitat Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003; 15: 785–90PubMedCrossRef Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003; 15: 785–90PubMedCrossRef
7.
Zurück zum Zitat Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis. 2005; 46: 754–9PubMedCrossRef Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis. 2005; 46: 754–9PubMedCrossRef
8.
Zurück zum Zitat Leboit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol. 2003; 139: 928–30PubMedCrossRef Leboit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol. 2003; 139: 928–30PubMedCrossRef
9.
Zurück zum Zitat McNeill AM, Barr RJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol. 2002; 41: 364–7PubMedCrossRef McNeill AM, Barr RJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol. 2002; 41: 364–7PubMedCrossRef
10.
Zurück zum Zitat Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001; 23: 38–93 Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001; 23: 38–93
11.
Zurück zum Zitat Quan TE, Cowper S, Wu SP, et al. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004; 36: 598–606PubMedCrossRef Quan TE, Cowper S, Wu SP, et al. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004; 36: 598–606PubMedCrossRef
12.
Zurück zum Zitat Yang L, Scott PG, Giuffre J, et al. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest. 2002; 82: 1183–92PubMed Yang L, Scott PG, Giuffre J, et al. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest. 2002; 82: 1183–92PubMed
13.
Zurück zum Zitat Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear [letter]. Am J Dermatopathol. 2003; 25: 358PubMedCrossRef Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear [letter]. Am J Dermatopathol. 2003; 25: 358PubMedCrossRef
14.
Zurück zum Zitat Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor betal expression in affected skin. Arthritis Rheum. 2004; 50: 2660–6PubMedCrossRef Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor betal expression in affected skin. Arthritis Rheum. 2004; 50: 2660–6PubMedCrossRef
15.
Zurück zum Zitat Ortonne N, Lipsker D, Chantrel F, et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol. 2004; 150: 1050–2PubMedCrossRef Ortonne N, Lipsker D, Chantrel F, et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol. 2004; 150: 1050–2PubMedCrossRef
16.
Zurück zum Zitat Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003; 114: 563–72PubMedCrossRef Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003; 114: 563–72PubMedCrossRef
17.
Zurück zum Zitat Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? [letter]. Arch Dermatol. 2004; 140: 1401PubMedCrossRef Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? [letter]. Arch Dermatol. 2004; 140: 1401PubMedCrossRef
19.
Zurück zum Zitat Jan F, Segal JM, Dyer J, et al. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr. 2003; 143: 678–81PubMedCrossRef Jan F, Segal JM, Dyer J, et al. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr. 2003; 143: 678–81PubMedCrossRef
20.
Zurück zum Zitat Jain SM, Wesson S, Hassanein A, et al. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol. 2004; 19: 467–70PubMedCrossRef Jain SM, Wesson S, Hassanein A, et al. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol. 2004; 19: 467–70PubMedCrossRef
21.
Zurück zum Zitat Engelen JW, Kooistra MP, Canninga-van Dijk MR, et al. Nephrogenic fibrosing dermopathy. Ned Tijdschr Geneeskd. 2003; 147: 2435–8PubMed Engelen JW, Kooistra MP, Canninga-van Dijk MR, et al. Nephrogenic fibrosing dermopathy. Ned Tijdschr Geneeskd. 2003; 147: 2435–8PubMed
22.
Zurück zum Zitat Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant. 2004; 19: 469–73PubMedCrossRef Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant. 2004; 19: 469–73PubMedCrossRef
23.
Zurück zum Zitat Scleromxoedema-like changes in four renal dialysis patients. Br J Dermatol 2003; 148: 563–8 Scleromxoedema-like changes in four renal dialysis patients. Br J Dermatol 2003; 148: 563–8
24.
Zurück zum Zitat Panda S, Bandyopadhyay D, Tarafder A. Nephrogenic fibrosing dermopathy: a series in a non-Western population. J Am Acad Dermatol. 2006; 54: 155–9PubMedCrossRef Panda S, Bandyopadhyay D, Tarafder A. Nephrogenic fibrosing dermopathy: a series in a non-Western population. J Am Acad Dermatol. 2006; 54: 155–9PubMedCrossRef
25.
Zurück zum Zitat Markus JS, James AJ, Nunez-Gussman JK, et al. Nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2005; 52: 166–7PubMedCrossRef Markus JS, James AJ, Nunez-Gussman JK, et al. Nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2005; 52: 166–7PubMedCrossRef
26.
Zurück zum Zitat Hancox JG, Mengesha YM, Sangueza OP, et al. Nephrogenic fibrosing dermopathy after five days of hemodialysis. J Drugs Dermatol. 2003; 2: 550–3PubMed Hancox JG, Mengesha YM, Sangueza OP, et al. Nephrogenic fibrosing dermopathy after five days of hemodialysis. J Drugs Dermatol. 2003; 2: 550–3PubMed
27.
Zurück zum Zitat Taylor EN, Henderson JM, Rennke HG, et al. Traumatic calcinosis cutis in a dialysis patient. Am J Kidney Dis. 2004; 44: e18–21PubMedCrossRef Taylor EN, Henderson JM, Rennke HG, et al. Traumatic calcinosis cutis in a dialysis patient. Am J Kidney Dis. 2004; 44: e18–21PubMedCrossRef
28.
Zurück zum Zitat Ruiz-Genao DP, Pascual-Lopez MP, Fraga S, et al. Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy. J Cutan Pathol. 2005; 32: 172–5PubMedCrossRef Ruiz-Genao DP, Pascual-Lopez MP, Fraga S, et al. Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy. J Cutan Pathol. 2005; 32: 172–5PubMedCrossRef
29.
Zurück zum Zitat Hershko K, Hull C, Ettefagh L, et al. A variant of nephrogenic fibrosing dermopathy with osteoclast-like giant cells: a syndrome of dysregulated matrix remodeling?. J Cutan Pathol. 2004; 31: 262–5PubMedCrossRef Hershko K, Hull C, Ettefagh L, et al. A variant of nephrogenic fibrosing dermopathy with osteoclast-like giant cells: a syndrome of dysregulated matrix remodeling?. J Cutan Pathol. 2004; 31: 262–5PubMedCrossRef
30.
Zurück zum Zitat Edsall LC, English III JC, Teague MW, et al. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy [published erratum appears in J Cutan Pathol 2004; 31: 518]. J Cutan Pathol. 2004; 31: 247–53PubMedCrossRef Edsall LC, English III JC, Teague MW, et al. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy [published erratum appears in J Cutan Pathol 2004; 31: 518]. J Cutan Pathol. 2004; 31: 247–53PubMedCrossRef
31.
Zurück zum Zitat Glaich AS, Martinelli PT, Markus RF, et al. Generalized elastolysis following nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2005; 53: 174–6PubMedCrossRef Glaich AS, Martinelli PT, Markus RF, et al. Generalized elastolysis following nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2005; 53: 174–6PubMedCrossRef
32.
Zurück zum Zitat Chin H, Wells G, Carag H, et al. Nephrogenic fibrosing dermopathy: a rare entity in patients awaiting liver transplantation. Liver Transpl. 2004; 10: 465–6CrossRef Chin H, Wells G, Carag H, et al. Nephrogenic fibrosing dermopathy: a rare entity in patients awaiting liver transplantation. Liver Transpl. 2004; 10: 465–6CrossRef
33.
Zurück zum Zitat Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003; 25: 204–9PubMedCrossRef Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003; 25: 204–9PubMedCrossRef
34.
Zurück zum Zitat Gremmels JM, Kirk GA. Two patients with abnormal skeletal muscle uptake of Tc-99m hydroxymethylene diphosphonate following liver transplant: nephrogenic fibrosing dermopathy and graft vs host disease. Clin Nucl Med. 2004; 29: 694–7PubMedCrossRef Gremmels JM, Kirk GA. Two patients with abnormal skeletal muscle uptake of Tc-99m hydroxymethylene diphosphonate following liver transplant: nephrogenic fibrosing dermopathy and graft vs host disease. Clin Nucl Med. 2004; 29: 694–7PubMedCrossRef
35.
Zurück zum Zitat Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve. 2004; 30: 569–77PubMedCrossRef Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve. 2004; 30: 569–77PubMedCrossRef
36.
Zurück zum Zitat Bardin T. Musculoskeletal manifestations of chronic renal failure. Curr Opin Rheumatol. 2003; 15: 48–54PubMedCrossRef Bardin T. Musculoskeletal manifestations of chronic renal failure. Curr Opin Rheumatol. 2003; 15: 48–54PubMedCrossRef
37.
Zurück zum Zitat Hauser C, Kaya G, Chizzolini C. Nephrogenic fibrosing dermopathy in a renal transplant recipient with tubulointerstitial nephritis and uveitis. Dermatology. 2004; 209: 50–2PubMedCrossRef Hauser C, Kaya G, Chizzolini C. Nephrogenic fibrosing dermopathy in a renal transplant recipient with tubulointerstitial nephritis and uveitis. Dermatology. 2004; 209: 50–2PubMedCrossRef
38.
Zurück zum Zitat Obermoser G, Emberger M, Wieser M, et al. Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus. Lupus. 2004; 13: 609–12PubMedCrossRef Obermoser G, Emberger M, Wieser M, et al. Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus. Lupus. 2004; 13: 609–12PubMedCrossRef
39.
Zurück zum Zitat Streams BN, Liu V, Liegeois N, et al. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol. 2003; 48: 42–7PubMedCrossRef Streams BN, Liu V, Liegeois N, et al. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol. 2003; 48: 42–7PubMedCrossRef
40.
Zurück zum Zitat Perazella MA, Ishibe S, Perazella MA, et al. Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease. Semin Dial. 2003; 16: 276–80PubMedCrossRef Perazella MA, Ishibe S, Perazella MA, et al. Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease. Semin Dial. 2003; 16: 276–80PubMedCrossRef
41.
Zurück zum Zitat Gambichler T, Paech V, Kreuter A, et al. Nephrogenic fibrosing dermopathy. Clin Exp Dermatol. 2004; 29: 258–60PubMedCrossRef Gambichler T, Paech V, Kreuter A, et al. Nephrogenic fibrosing dermopathy. Clin Exp Dermatol. 2004; 29: 258–60PubMedCrossRef
42.
Zurück zum Zitat Kucher C, Xu X, P asha T, et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol. 2005; 32: 484–90PubMedCrossRef Kucher C, Xu X, P asha T, et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol. 2005; 32: 484–90PubMedCrossRef
43.
Zurück zum Zitat Gilliet M, Cozzio A, Burg G, et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005; 152: 531–6PubMedCrossRef Gilliet M, Cozzio A, Burg G, et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005; 152: 531–6PubMedCrossRef
44.
Zurück zum Zitat Schmook T, Budde K, Ulrich C, et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant. 2005; 20: 220–2PubMedCrossRef Schmook T, Budde K, Ulrich C, et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant. 2005; 20: 220–2PubMedCrossRef
45.
Zurück zum Zitat Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol. 2004; 150: 596–7PubMedCrossRef Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol. 2004; 150: 596–7PubMedCrossRef
46.
Zurück zum Zitat Kafi R, Fisher GJ, Quan T, et al. UV-Al phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004; 140: 1322–4PubMedCrossRef Kafi R, Fisher GJ, Quan T, et al. UV-Al phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004; 140: 1322–4PubMedCrossRef
47.
Zurück zum Zitat Lauchli S, Zortea-Caflisch C, Nestle FO, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004; 208: 278–80PubMedCrossRef Lauchli S, Zortea-Caflisch C, Nestle FO, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004; 208: 278–80PubMedCrossRef
48.
Zurück zum Zitat Tan AW, Tan SH, Lian TY, et al. A case of nephrogenic fibrosing dermopathy. Ann Acad Med Singapore. 2004; 33: 527–9PubMed Tan AW, Tan SH, Lian TY, et al. A case of nephrogenic fibrosing dermopathy. Ann Acad Med Singapore. 2004; 33: 527–9PubMed
49.
Zurück zum Zitat Caldwell-Brown D, Stern RS, Lin AN, et al. Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group. N Engl J Med. 1992; 327: 163–7PubMedCrossRef Caldwell-Brown D, Stern RS, Lin AN, et al. Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group. N Engl J Med. 1992; 327: 163–7PubMedCrossRef
50.
Zurück zum Zitat Mesa RA, Elliott MA, Schroeder G, et al. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004; 79: 883–9PubMedCrossRef Mesa RA, Elliott MA, Schroeder G, et al. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004; 79: 883–9PubMedCrossRef
51.
Zurück zum Zitat Moschella SL, Kay J, Mackool BT, et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises: case 35-2004: a 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med. 2004; 351: 2219–27PubMedCrossRef Moschella SL, Kay J, Mackool BT, et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises: case 35-2004: a 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med. 2004; 351: 2219–27PubMedCrossRef
52.
Zurück zum Zitat Alopecia neoplastica responsive to tamoxifen. J R Soc Med 1990; 83: 647–8 Alopecia neoplastica responsive to tamoxifen. J R Soc Med 1990; 83: 647–8
53.
Zurück zum Zitat Taylor RA, Levine JM, Jimenez SA. Case 35-2004: nephrogenic fibrosing dermopathy [letter]. N Engl J Med. 2005; 352: 1723PubMedCrossRef Taylor RA, Levine JM, Jimenez SA. Case 35-2004: nephrogenic fibrosing dermopathy [letter]. N Engl J Med. 2005; 352: 1723PubMedCrossRef
54.
Zurück zum Zitat Cowper SE, Bucala R, LeBoit PE. Case 35-2004: nephrogenic fibrosing dermopathy [letter]. N Engl J Med. 2005; 352: 1723PubMedCrossRef Cowper SE, Bucala R, LeBoit PE. Case 35-2004: nephrogenic fibrosing dermopathy [letter]. N Engl J Med. 2005; 352: 1723PubMedCrossRef
55.
Zurück zum Zitat Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis. 2005; 46: 763–5PubMedCrossRef Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis. 2005; 46: 763–5PubMedCrossRef
56.
Zurück zum Zitat Dundova I, Treska V, Simanek V, et al. Nephrogenic fibrosing dermopathy: a case study. Transplant Proc. 2005; 37: 4187–90PubMedCrossRef Dundova I, Treska V, Simanek V, et al. Nephrogenic fibrosing dermopathy: a case study. Transplant Proc. 2005; 37: 4187–90PubMedCrossRef
57.
Zurück zum Zitat Dawn G, Holmes SC. Scleromyxoedema-like eruption following haemodialysis or nephrogenic fibrosing dermopathy?. Br J Dermatol. 2004; 150: 167–8PubMedCrossRef Dawn G, Holmes SC. Scleromyxoedema-like eruption following haemodialysis or nephrogenic fibrosing dermopathy?. Br J Dermatol. 2004; 150: 167–8PubMedCrossRef
58.
Zurück zum Zitat Brisch M, Schneider T, Requena L, et al. Nephrogenic fibrosing dermopathy. J Dtsch Dermatol Ges. 2003; 1: 464–7PubMedCrossRef Brisch M, Schneider T, Requena L, et al. Nephrogenic fibrosing dermopathy. J Dtsch Dermatol Ges. 2003; 1: 464–7PubMedCrossRef
59.
Zurück zum Zitat Dupont A, Majithia V, Ahmad S, et al. Nephrogenic fibrosing dermopathy, a new mimicker of systemic sclerosis. Am J Med Sci. 2005; 330: 192–4PubMedCrossRef Dupont A, Majithia V, Ahmad S, et al. Nephrogenic fibrosing dermopathy, a new mimicker of systemic sclerosis. Am J Med Sci. 2005; 330: 192–4PubMedCrossRef
60.
Zurück zum Zitat Silver RM. Pathophysiology of the eosinophilia-myalgia syndrome. J Rheumatol Suppl. 1996; 46: 26–36PubMed Silver RM. Pathophysiology of the eosinophilia-myalgia syndrome. J Rheumatol Suppl. 1996; 46: 26–36PubMed
61.
Zurück zum Zitat Matsuzaki Y, Nakano A, Jiang QJ, et al. Tissue-specific expression of the ABCC6 gene. J Invest Dermatol. 2005; 125: 900–5PubMed Matsuzaki Y, Nakano A, Jiang QJ, et al. Tissue-specific expression of the ABCC6 gene. J Invest Dermatol. 2005; 125: 900–5PubMed
62.
Zurück zum Zitat Sapadin AN, Lebwohl MG, Teich SA, et al. Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks: apparent regression with hemodialysis. J Am Acad Dermatol. 1998; 39: 338–44PubMedCrossRef Sapadin AN, Lebwohl MG, Teich SA, et al. Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks: apparent regression with hemodialysis. J Am Acad Dermatol. 1998; 39: 338–44PubMedCrossRef
63.
Zurück zum Zitat Abe R, Donnelly SC, Peng T, et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 2001; 166: 7556–62PubMed Abe R, Donnelly SC, Peng T, et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 2001; 166: 7556–62PubMed
Metadaten
Titel
Nephrogenic Fibrosing Dermopathy
A Comprehensive Review for the Dermatologist
verfasst von
Dr Noah Scheinfeld
Publikationsdatum
01.08.2006
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 4/2006
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200607040-00005

Weitere Artikel der Ausgabe 4/2006

American Journal of Clinical Dermatology 4/2006 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.